AstraZeneca picks Cambridge site as ground zero for R&D reinvention

John Carroll

Over the next three years the pharma company plans to build a $ 500 million complex on its new campus that will house its U.K. operations for biologics and small molecule research as well as the corporate staff now operating in London.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS